Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma.

The article reviews recent findings on the efficacy of elotuzumab in multiple myeloma treatment. Topics include the impact of elotuzumab combined with other agents like lenalidomide and dexamethasone on overall response rates and survival, the influence of prior daratumumab treatment on the efficacy of elotuzumab-based regimens, and the results of a prospective phase II study evaluating the use of elotuzumab in patients with daratumumab-refractory multiple myeloma.